|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12345678910111213...4041» |
- Phase classification, Enrollment change, Trial withdrawal, Stroma: Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis (clinicaltrials.gov) - Sep 1, 2017
P=N/A, N=0, Withdrawn, Sponsor: Ageless Regenerative Institute
Phase classification: P1/2 --> P=N/A | N=50 --> 0 | Recruiting --> Withdrawn
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, P1 data, Enrollment change, Trial primary completion date, MRI: A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients (clinicaltrials.gov) - Aug 30, 2017
P1, N=8, Completed, Sponsor: Johns Hopkins University
Phase classification: P1/2 --> P=N/A | N=50 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | N=12 --> 8 | Trial primary completion date: Dec 2017 --> Aug 2017
- ||| Trial completion, Phase classification: Investigation of Sacroiliac Fusion Treatment (INSITE) (clinicaltrials.gov) - Aug 25, 2017
P=N/A, N=159, Completed, Sponsor: SI-BONE, Inc.
Recruiting --> Completed | N=12 --> 8 | Trial primary completion date: Dec 2017 --> Aug 2017 Active, not recruiting --> Completed | Phase classification: P4 --> PN/A
- |||||| everolimus / Generic mfg.
Enrollment open: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Aug 24, 2017
P3, N=355, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Phase classification: P4 --> PN/A Active, not recruiting --> Recruiting
- | Enrollment closed, Trial primary completion date: NUTRISEP: Evaluation of Nutritional Status and Fatigue in Patients With Multiple Sclerosis (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=360, Active, not recruiting, Sponsor: Lille Catholic University
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Jun 2017
- ||||||| mecobalamin (E0302) / Eisai
Trial completion, Enrollment change: A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Aug 23, 2017
P2/3, N=135, Completed, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Jun 2017 Active, not recruiting --> Completed | N=300 --> 135
- dalfampridine / Generic mfg.
Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Aug 18, 2017
P2, N=25, Active, not recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | N=300 --> 135 Trial primary completion date: Nov 2016 --> May 2017
- | Trial completion, Trial primary completion date: PHYSACTINMS: Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes (clinicaltrials.gov) - Aug 18, 2017
P=N/A, N=18, Completed, Sponsor: Kessler Foundation
Trial primary completion date: Nov 2016 --> May 2017 Recruiting --> Completed | Trial primary completion date: Nov 2015 --> Jun 2016
- | arimoclomol (OR-01) / Orphazyme, KemPharm
Trial completion, Trial primary completion date: Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Aug 14, 2017
P2/3, N=38, Completed, Sponsor: University of Miami
Recruiting --> Completed | Trial primary completion date: Nov 2015 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2014
- | Trial completion, Trial primary completion date, IO biomarker: Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Aug 14, 2017
P=N/A, N=629, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2014 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2014
- | Trial completion: Psychological Treatments for Scleroderma (clinicaltrials.gov) - Aug 8, 2017
P2, N=89, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2014 No longer recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Evaluation of Coagulation in Multiple Sclerosis (clinicaltrials.gov) - Jul 28, 2017
P=N/A, N=69, Completed, Sponsor: Bastyr University
No longer recruiting --> Completed Recruiting --> Completed | N=100 --> 69 | Trial primary completion date: Dec 2016 --> May 2016
- | mexiletine / Generic mfg.
Enrollment change: Mexiletine for the Treatment of Muscle Cramps in ALS (clinicaltrials.gov) - Jul 26, 2017
P4, N=23, Completed, Sponsor: Bjorn Oskarsson, MD
Recruiting --> Completed | N=100 --> 69 | Trial primary completion date: Dec 2016 --> May 2016 N=30 --> 23
- Trial primary completion date, Stroma: Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis (clinicaltrials.gov) - Jul 21, 2017
P1/2, N=50, Recruiting, Sponsor: Ageless Regenerative Institute
N=30 --> 23 Trial primary completion date: Apr 2017 --> Dec 2018
- | Trial completion: The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort (clinicaltrials.gov) - Jul 21, 2017
P=N/A, N=973, Completed, Sponsor: Duke University
Trial primary completion date: Apr 2017 --> Dec 2018 Terminated --> Completed
- | Enrollment status, Trial primary completion date: Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis (clinicaltrials.gov) - Jul 19, 2017
P=N/A, N=1920, Enrolling by invitation, Sponsor: University of California, San Francisco
Terminated --> Completed Recruiting --> Enrolling by invitation | Trial primary completion date: Apr 2017 --> Apr 2018
- |||| MIS416 / Amplia Therap
Trial completion: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jul 17, 2017
P2b, N=93, Completed, Sponsor: Innate Immunotherapeutics
Recruiting --> Enrolling by invitation | Trial primary completion date: Apr 2017 --> Apr 2018 Active, not recruiting --> Completed
- | Betaseron (IFN-?-1b) / Bayer
Phase classification: Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Jul 12, 2017
P=N/A, N=68, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Phase classification: P4 --> P=N/A
- | ATX-MS-1467 / Apitope
Enrollment change: ATX-MS-1467 in Multiple Sclerosis (clinicaltrials.gov) - Jul 2, 2017
P2, N=37, Completed, Sponsor: Merck KGaA
Phase classification: P4 --> P=N/A N=93 --> 37
- | Trial completion, Enrollment change, Trial primary completion date: Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS) (clinicaltrials.gov) - Jul 2, 2017
P=N/A, N=32, Completed, Sponsor: Kessler Foundation
N=93 --> 37 Recruiting --> Completed | N=48 --> 32 | Trial primary completion date: Nov 2015 --> Apr 2017
- | Trial completion, MRI: Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=94, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed | N=48 --> 32 | Trial primary completion date: Nov 2015 --> Apr 2017 Recruiting --> Completed
- | Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 30, 2017
P2, N=16, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Physiologic Studies of Spasticity (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=48, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: Assessment of Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=1388, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Recruiting --> Completed
- | Trial completion: AERCONN: Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=68, Completed, Sponsor: Universitätsklinikum Hamburg-Eppendorf
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial termination, Trial primary completion date: The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=973, Terminated, Sponsor: Duke University
Active, not recruiting --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Aug 2017 --> May 2017
- | Enrollment change, Trial termination: Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis (clinicaltrials.gov) - May 31, 2017
P1/2, N=9, Terminated, Sponsor: Nicolas Hunzelmann
Active, not recruiting --> Terminated | Trial primary completion date: Aug 2017 --> May 2017 N=60 --> 9 | Recruiting --> Terminated; lack of recruitement
- | Biomarker, Trial completion, Enrollment change: A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers (clinicaltrials.gov) - May 30, 2017
P=N/A, N=139, Completed, Sponsor: Massachusetts General Hospital
N=60 --> 9 | Recruiting --> Terminated; lack of recruitement Recruiting --> Completed | N=250 --> 139
- ||| Trial completion, Enrollment change, Patient reported outcomes: PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod (clinicaltrials.gov) - May 25, 2017
P=N/A, N=114, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=250 --> 139 Recruiting --> Completed | N=240 --> 114
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion: Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (clinicaltrials.gov) - May 25, 2017
P=N/A, N=1085, Completed, Sponsor: Bayer
Recruiting --> Completed | N=240 --> 114 Active, not recruiting --> Completed
- | fingolimod / Generic mfg.
Trial completion: Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. (clinicaltrials.gov) - May 24, 2017
P=N/A, N=125, Completed, Sponsor: University of Southern California
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: FACTSEP: Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis (clinicaltrials.gov) - May 8, 2017
P3, N=59, Completed, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Physical Telerehabilitation in Veterans With Multiple Sclerosis (clinicaltrials.gov) - May 5, 2017
P=N/A, N=74, Completed, Sponsor: University of Maryland
Active, not recruiting --> Completed Recruiting --> Completed | N=170 --> 74 | Trial primary completion date: Jul 2015 --> Apr 2017
- |||| Trial completion, Trial primary completion date: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - May 4, 2017
P4, N=349, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=170 --> 74 | Trial primary completion date: Jul 2015 --> Apr 2017 Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Dec 2015
- | Trial completion, Trial primary completion date: Tuberous Sclerosis Complex Natural History Study: Renal Manifestations (clinicaltrials.gov) - May 4, 2017
P=N/A, N=450, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Completed | Trial primary completion date: Oct 2016 --> Dec 2015 Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Sep 2013
- | Trial completion, Phase classification, Enrollment change: CISAVID: Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome (clinicaltrials.gov) - May 3, 2017
P1/2, N=64, Completed, Sponsor: University College Dublin
Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Sep 2013 Active, not recruiting --> Completed | Phase classification: P2 --> P1/2 | N=84 --> 64
- Trial primary completion date: Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - May 2, 2017
P=N/A, N=50, Active, not recruiting, Sponsor: University at Buffalo
Active, not recruiting --> Completed | Phase classification: P2 --> P1/2 | N=84 --> 64 Trial primary completion date: Oct 2016 --> Sep 2018
- | ambrisentan / Generic mfg.
Trial completion, Combination therapy: Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis (clinicaltrials.gov) - May 2, 2017
P=N/A, N=15, Completed, Sponsor: University of Pennsylvania
Trial primary completion date: Oct 2016 --> Sep 2018 Active, not recruiting --> Completed
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion, Trial primary completion date: Nilotinib in the Treatment of Systemic Sclerosis (clinicaltrials.gov) - Apr 28, 2017
P2a, N=10, Completed, Sponsor: Hospital for Special Surgery, New York
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2012 --> Jul 2014
- | atorvastatin / Generic mfg.
Trial completion: STAYCIS: Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis (clinicaltrials.gov) - Apr 27, 2017
P2, N=82, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Jul 2012 --> Jul 2014 Active, not recruiting --> Completed
- | Enrollment change: Power Over Pain (POP) Study (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=177, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed N=144 --> 177
- | donepezil / Generic mfg.
Enrollment change: Improving Memory in Patients With Multiple Sclerosis (clinicaltrials.gov) - Apr 25, 2017
P3, N=0, Withdrawn, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=144 --> 177 N=60 --> 0
- | Trial primary completion date: SOD1: Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=30, Recruiting, Sponsor: University of North Carolina, Chapel Hill
N=60 --> 0 Trial primary completion date: Aug 2016 --> Aug 2017
- | Trial completion, Phase classification, Enrollment change, Trial primary completion date: MSPi: Mindfulness Meditation for Subjects With Severe Speech and Physical Impairments (clinicaltrials.gov) - Apr 13, 2017
P=N/A, N=8, Completed, Sponsor: Oregon Health and Science University
Trial primary completion date: Aug 2016 --> Aug 2017 Active, not recruiting --> Completed | Phase classification: P2 --> PN/A | N=10 --> 8 | Trial primary completion date: Aug 2020 --> Oct 2016
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion, Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Apr 12, 2017
P2, N=7, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Active, not recruiting --> Completed | Phase classification: P2 --> PN/A | N=10 --> 8 | Trial primary completion date: Aug 2020 --> Oct 2016 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2015
- | Trial primary completion date: AHOD0031: Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease (clinicaltrials.gov) - Apr 12, 2017
P3, N=1734, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2015 Trial primary completion date: Mar 2012 --> Aug 2012
- | Phase classification, Trial primary completion date, Immunomodulating: Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Apr 11, 2017
P1, N=16, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Trial primary completion date: Mar 2012 --> Aug 2012 Phase classification: P=N/A --> P1 | Trial primary completion date: Mar 2017 --> Apr 2016
- | Trial primary completion date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Apr 7, 2017
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Phase classification: P=N/A --> P1 | Trial primary completion date: Mar 2017 --> Apr 2016 Trial primary completion date: Jan 2017 --> Dec 2017
- | Trial completion, Video: Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=30, Completed, Sponsor: Ohio State University
Trial primary completion date: Jan 2017 --> Dec 2017 Active, not recruiting --> Completed
- | Trial completion: SOCOG-MS: Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=35, Completed, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Recruiting --> Completed